OTC: VREOF · Life Sciences · 4 alerts · CIK 1771706
Share price
$6.29Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vireo Growth Inc. filings on SEC EDGAR ↗
Vireo Growth Inc. reported a significant revenue increase to $253.7 million for the quarter ended September 30, 2026, compared to $91.7 million in the prior year, driven by multiple acquisitions including Eaze, Hawthorne, and C21. Despite higher gross profits, the company recorded a net loss of $24.0 million for the quarter, impacted by substantial current income tax expenses and transaction-related costs.
Vireo Growth is aggressively consolidating the cannabis market through acquisitions, achieving a $1 billion revenue run rate while pivoting to formal sequential guidance and disciplined cost management.
Vireo Growth reported Q3 2026 GAAP revenue of $253.7 million, a 177% increase year-over-year driven by recent M&A activity. The company achieved an annualized revenue run rate exceeding $1 billion and ended the quarter with $106.8 million in cash. Management highlighted the continued execution of its consolidation strategy and the pending merger with Planet 13.
Vireo Growth $60M Debt Financing with Needham Bank
Vireo Growth Inc. entered into a $60 million term loan agreement with Needham Bank at a fixed interest rate of 8.50% per annum. The proceeds were used to refinance $49 million of existing senior debt related to its New York cultivation facility and to finance the $11 million acquisition of its Palatka, Florida cultivation facility. The loan is secured by first-priority mortgages on these properties and matures in April 2034.